Abivax shares jumped after newly reported ABTECT Maintenance Part 2 results for obefazimod in adults with moderately to severely active ulcerative colitis. In the supplemental portion, 37.2% of induction nonresponders achieved clinical remission and 34.5% achieved endoscopic remission at Week 44 on continued 50 mg treatment. Abivax also reported response recapture in patients escalated to 50 mg after relapse during ABTECT Maintenance Part 1, with clinical remission achieved in 45.5% of that relapsed subgroup. The company said these findings support a practical dose-escalation strategy for regaining and sustaining disease control over time. Importantly for investors, Abivax stated that no new safety signals emerged since earlier disclosures of malignancies in nine patients among 580 enrolled. The updated dataset included four non-melanoma skin cancer cases, attributed to established risk factors, and exposure-adjusted incidence rates for malignancies were said to fall within pre-defined background reference ranges from prior UC studies.